Application of litamilast in preparation of medicine for treating retinal artery occlusion injury
Through the use of ritast, the problem of lack of treatment methods for retinal artery occlusion was solved, and the effect of reducing retinal artery occlusion and neuroinflammatory damage was achieved, providing new uses and treatment ideas for retinal artery occlusion.
Patent Information
- Application Number
- CN202411082094.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-08
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-08-08
AI Technical Summary
The prior art lacks effective drugs for treating retinal artery occlusion, which makes it difficult for patients to achieve satisfactory improvement in vision loss and lacks treatment methods.
Litast is used as a novel small molecule integrin antagonist, administered through glass cavity injection, to alleviate retinal artery occlusion damage and apoptosis of retinal ganglion cells, inhibit inflammatory infiltration and activation of microglia. Applied to neuroinflammatory damage caused by retinal artery occlusion.
Litast effectively reduces retinal artery occlusion damage and retinal ganglion cells, inhibits inflammatory infiltration and activation of microglia, provides new uses for retinal artery occlusion and has wide application prospects.
Smart Images

Figure CN118903130A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of ophthalmic drugs, and in particular to an application of lifalast in preparing a drug for treating retinal artery occlusion damage. Background Art
[0002] Retinal artery occlusion (RAO) is characterized by painless, sudden unilateral vision loss. The sudden interruption of blood flow leads to massive death of retinal ganglion cells (RGC) and strong inflammatory response, especially activation of microglia, resulting in loss of visual function. Currently, the treatment measures for RAO mainly include thrombolytic therapy, hyperbaric oxygen therapy, lowering intraocular pressure and eye massage. In actual clinical work, most patients have missed the time window for thrombolytic therapy. Although other treatment measures can relieve the symptoms of some patients, it is difficult to achieve satisfactory vision improvement. The pathogenic factors of ROA are complex, and there is a lack of rapid and effective treatment drugs and programs in clinical practice. Therefore, it is of great research significance to develop low-cost drugs for the treatment of retinal artery damage.
[0003] Lifitegrast is a new type of small molecule integrin antagonist, a synthetic compound with a molecular formula of C 29 H 24 Cl2N2O7S, CAS number is 1025967-78-5, the structural formula is as follows:
[0004]
[0005] Studies have confirmed that lifastat is a new inhibitor of intercellular adhesion factors, which can work by blocking the binding between intercellular adhesion molecule-1 and integrin protein lymphocyte function-associated antigen-1. In July 2016, the U.S. Food and Drug Administration (FDA) officially approved the application of 5% lifastat eye drops (trade name XiidraTM), which is the first new drug approved by the FDA to improve and treat dry eye symptoms. The clinical trials of this drug mainly include a 12-week Phase II clinical trial and three 12-week Phase III clinical trials for patients with dry eye. The results of the study fully demonstrated the effectiveness and safety of the drug.
[0006] Retinal artery occlusion damage belongs to the category of fundus diseases. There is currently no effective treatment for this disease. There are no research reports on levofloxacin in this disease. Therefore, it is necessary to develop new therapeutic drugs for the treatment of retinal artery occlusion damage.
[0007] The present invention intends to develop a new use of lifalast in retinal artery occlusion injury, and provide treatment methods and ideas for clinical research. Summary of the invention
[0008] The purpose of the present invention is to provide a new use of lifalast to solve the problem of lack of treatment methods for retinal artery occlusion. Through experiments, it was found that lifalast can effectively reduce the damage of retinal artery occlusion and apoptosis of retinal ganglion cells in mice. At the same time, lifalast also has the effect of inhibiting retinal inflammatory infiltration and activation of microglia. At the same time, lifalast also has the effect of reducing retinal ganglion cell damage, can be used for related diseases such as neuroinflammatory damage caused by retinal artery occlusion, and has broad application prospects.
[0009] The purpose of the present invention is achieved through the following technical solutions:
[0010] On the one hand, the purpose of the present invention is to provide a use of lifalast in the preparation of a medicament for treating retinal artery occlusion damage.
[0011] In a second aspect, the present invention aims to provide a use of a composition containing lifalast in the preparation of a medicament for treating retinal artery occlusion damage.
[0012] In a third aspect, the present invention aims to provide a use of lifalast in the preparation of a drug for inhibiting the gene expression of at least one of Inos, Tnf-α, Il-1β, and IL-6.
[0013] In a fourth aspect, the present invention aims to provide a composition containing lifalast for use in the preparation of a drug for inhibiting the gene expression of at least one of Inos, Tnf-α, Il-1β, and IL-6.
[0014] Fifthly, use of lifalast in the preparation of a drug for alleviating apoptosis of retinal ganglion cells.
[0015] The administration method of the drug is: intravitreal injection.
[0016] The dosage is 0.1-1 μg.
[0017] The drug acts on the microglial cell line BV2 or the retinal progenitor cell line R28.
[0018] In a sixth aspect, the present invention aims to provide a drug for treating retinal artery occlusion damage, comprising lifalast.
[0019] In a seventh aspect, an object of the present invention is to provide a drug for inhibiting the gene expression of at least one of Inos, Tnf-α, Il-1β, and IL-6, comprising lifalast.
[0020] It also comprises pharmaceutically acceptable salts and pharmaceutically acceptable carriers to form clinically acceptable drugs or preparations.
[0021] The carrier is at least one of conventional diluents, excipients, fillers, adhesives, wetting agents, disintegrants, absorption promoters, surfactants, adsorption carriers, lubricants, flavoring agents, and sweeteners in the pharmaceutical field.
[0022] The present invention has the following advantages and beneficial effects:
[0023] The present invention discovers a new use of Litahist to solve the problem of lack of treatment methods for retinal artery occlusion. Litahist can effectively reduce retinal artery occlusion damage and apoptosis of retinal ganglion cells. At the same time, Litahist also has the effect of inhibiting retinal inflammatory infiltration and microglial activation.
[0024] Lifalast also has the effect of reducing retinal ganglion cell damage and can be used for related diseases such as neuroinflammatory damage caused by retinal artery occlusion, and has broad application prospects.
[0025] The nilotamidate of the present invention has an effect of inhibiting microglial activation, and the target of the effect is the microglial cell line BV2.
[0026] The object of the functional effect of ritamilast in the present invention on alleviating retinal ganglion cell damage is the retinal progenitor cell line R28. BRIEF DESCRIPTION OF THE DRAWINGS
[0027] Figure 1 The electroretinogram (ERG) test results of mice in Example 2 are as follows;
[0028] Figure 2 This is a picture of the mouse retinal HE staining pathological results in Example 2;
[0029] Figure 3 This is the picture of the RGC results of the immunofluorescence staining of the mouse retina in Example 2;
[0030] Figure 4 The effects of different concentrations of lifalast on the activity of BV2 cells in Example 3;
[0031] Figure 5 The effect of Lifalast on the expression of iNOS in BV2 cells in Example 3;
[0032] Figure 6 The effect of Litamilast in Example 3 on the expression of TNF-α in BV2 cells;
[0033] Figure 7 The effect of Litamilast on IL-1β expression in BV2 cells in Example 3;
[0034] Figure 8 The effect of Litamilast on IL-6 expression in BV2 cells in Example 3;
[0035] Fig. 9 This is the effect of Litamilast in Example 4 on oxygen-glucose deprivation injury in R28 cells. DETAILED DESCRIPTION
[0036] For a better understanding of the present invention, the following examples are provided to further illustrate the present invention, but the present invention is not limited to the following examples.
[0037] Now, various exemplary embodiments of the present invention are described in detail, which should not be considered as limiting the present invention, but should be understood as a more detailed description of certain aspects, features and embodiments of the present invention. It should be understood that the terms described in the present invention are only for describing specific embodiments and are not used to limit the present invention. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as commonly understood by conventional technicians in the field of the present invention. Although the present invention only describes preferred methods and materials, any methods and materials similar or equivalent to those described herein can also be used in the implementation or testing of the present invention. All documents mentioned in this specification are incorporated by reference to disclose and describe methods and / or materials related to the documents. In the event of a conflict with any incorporated document, the content of this specification shall prevail. Without departing from the scope or spirit of the present invention, various improvements and changes can be made to the specific embodiments of the present invention specification, which is obvious to those skilled in the art. Other embodiments obtained from the description of the present invention are obvious to technicians. The present invention description and examples are exemplary only. Regarding the "comprising", "including", "having", "containing" and the like used herein, they are all open terms, that is, they mean including but not limited to.
[0038] The present invention provides a mouse model of retinal ischemia-reperfusion injury. Further, the mouse model is a mouse model in which the pterygopalatine artery of the mouse is blocked for a period of time by surgery and then blood flow is restored to simulate the pathological process of the disease. Further, the pterygopalatine artery of the mouse is blocked for 2 hours and the blood reperfusion time is 7 days. Further, the occlusion of the pterygopalatine artery is achieved by a thread plug method. The present invention also develops a method for treating retinal artery occlusion injury in mice with lifastat. Further, the method is administered by intravitreal injection, the administration concentration is 1ug / ul, the volume is 1ul, and the administration time is once every two days. The present invention also provides a function of lifastat in inhibiting microglia activation, and further, the object of the action is the mouse microglia cell line BV2. The present invention also provides a function of lifastat in alleviating retinal ganglion cell damage, and the object of the action is the rat retinal progenitor cell line R28.
[0039] Example 1: Establishment of an animal model of retinal artery occlusion injury in mice:
[0040] Prepare 8-week-old C57BL / 6 male mice, whose weight is strictly controlled at 20-25g. Then prepare a gas anesthesia device. Anesthetize the mice with a nitrous oxide / oxygen mixture of 1.5-2% isoflurane through a rubber tube. The body temperature is maintained at 37±0.5℃ during the operation. The surgical instruments are disinfected with 75% alcohol. The mice are placed supine on a heating blanket and their necks are exposed. Then remove the hair on the neck of the mice, disinfect the skin and cut the skin along the midline of the neck. Pull open the neck gland with two forceps. Straightly separate the left common carotid artery, internal carotid artery and external carotid artery, but do not squeeze the closely attached nerves and veins. Then clamp the common carotid artery and internal carotid artery with a vascular clamp. Tie a knot at the distal end of the external carotid artery with 8-0 silk suture and a slipknot at the proximal end. Make a small incision between the two suture knots of the external carotid artery with ophthalmic scissors, and then insert a special line embolization into the external carotid artery and common carotid artery along the incision. Next, the internal carotid artery clamp was removed, the external carotid artery was cut at the opening of the external carotid artery, the suture was pulled back to the bifurcation of the common carotid artery, and reversed and inserted into the internal carotid artery, pterygopalatine artery, and ophthalmic artery. The suture was inserted into the end of the pterygopalatine artery, about 6 mm from the bifurcation. The tail of the suture was almost at the bifurcation, blocking the ophthalmic artery. The slipknot was then tied and the skin was sutured. The mice were free to move around during the arterial embolization. After 120 minutes of embolization, the suture was carefully removed from the pterygopalatine artery without major bleeding. The common carotid artery clamp was removed and arterial reperfusion was resumed. The skin wound was then sutured and the mice were fed routinely during reperfusion.
[0041] Example 2: In vivo effects of lifalast on retinal artery occlusion injury in mice:
[0042] 24 hours after the intravitreal injection of lifastat, the mouse retinal artery occlusion model was established. Seven days later, the mice were dark-adapted for 12 hours and the mouse retinal potential was measured. The mouse eyeballs were carefully removed and placed in a special eye fixative for more than 2 hours, then embedded in paraffin, sectioned and stained with HE. At the same time, the retinas of the other half of the mice were carefully separated under a surgical microscope to ensure the integrity of the retina and cell activity, and the retinas were fixed and immunofluorescently stained for Brn3a, and photographed and analyzed. Figure 1 This is the electroretinogram (ERG) test of mice in Example 2. It can be seen from the figure that the ERG amplitude of mice treated with lifalast is higher, the retinal thickness is increased compared with the control group, and the retinal ganglion density is increased, indicating that lifalast can effectively alleviate the damage of retinal ganglion cells in retinal artery occlusion and help restore visual function.
[0043] Figure 2 This is a picture of the pathological results of HE staining of the mouse retina in Example 2. It can be seen from the figure that the retinal thickness of the mice in the lifalast group increased and the damage was alleviated.
[0044] Figure 3 This is a picture of the RGC results of immunofluorescence staining of the mouse retina in Example 2. It can be seen from the figure that the number of ganglion cells in the retina increases after rifalast treatment.
[0045] Example 3: Effect of Lifalast on Microglial Activation and Metabolism:
[0046] The mouse microglial cell line BV2 was cultured in vitro, and the cells were plated and grouped in the logarithmic phase of cell growth, divided into a control group, a bacterial lipopolysaccharide (LPS) stimulation group, and an LPS+lifastat group. The LPS concentration was 200 ng / ml, and the lifastat concentration was 100 ng / ml. After 24 hours of stimulation, the cells were collected, RNA was extracted, and the concentration and quality of RNA were determined. Real-Time PCR was performed to detect the mRNA expression of Inos, Tnf-α, Il-1β, and IL-6, and the relative expression level changes were analyzed. The experimental results showed that lifastat can effectively inhibit the metabolism and activation of microglia.
[0047] Figure 4 This is the effect of different concentrations of lifalast on the activity of BV2 cells in Example 3. It can be seen from the figure that the concentration of lifalast from 0 to 100 ng / ml does not affect the activity of BV2 cells.
[0048] Figure 5 This is the effect of Litahist in Example 3 on the expression of iNOS in BV2 cells. As can be seen from the figure, Litahist can inhibit the gene expression level of iNOS and reduce the activation of microglia.
[0049] Figure 6 This is the effect of Litamilast in Example 3 on the expression of TNF-α in BV2 cells. As can be seen from the figure, Litamilast can inhibit the gene expression level of TNF-α and reduce the activation of microglia.
[0050] Figure 7 This is the effect of Litahist in Example 3 on the expression of IL-1β in BV2 cells. As can be seen from the figure, Litahist can inhibit the gene expression level of IL-1β and reduce the activation of microglia.
[0051] Figure 8 This is the effect of Litahist in Example 3 on the expression of IL-6 in BV2 cells. As can be seen from the figure, Litahist can inhibit the gene expression level of IL-6 and reduce the activation of microglia.
[0052] Example 4: Effects of Lifalast on Oxygen-Glucose Deprivation Injury of Retinal Ganglion Cells:
[0053] The rat retinal ganglion progenitor cell line R28 was cultured in vitro, plated and grouped in the logarithmic phase of cell growth, and subjected to oxygen-glucose deprivation treatment. Mice were deprived of oxygen and glucose for 6 hours, reoxygenated for 24 hours, and divided into a solvent control group and a levofloxacin group. The levofloxacin concentration was 100 ng / ml. The stimulation time was 24 hours. The cells were collected, digested into a single cell suspension, resuspended in PBS, and stained with Annexin V and PI. Flow cytometry was used to analyze cell apoptosis. Fig. 9 The effect of Litahist on oxygen-glucose deprivation injury of R28 cells in Example 4 shows that after treatment with Litahist, the proportion of apoptotic cells decreased significantly. The experimental results show that Litahist can reduce the damage of retinal ganglion cells.
[0054] The above is only a preferred embodiment of the present invention, which certainly cannot be used to limit the scope of rights of the present invention. It should be pointed out that for ordinary technicians in this technical field, several improvements and changes can be made without departing from the principle of the present invention, and these improvements and changes are also regarded as the protection scope of the present invention.
Claims
1. Use of lifalast in the preparation of a drug for treating retinal artery occlusion damage.
2. Use of a composition containing lifalast in the preparation of a drug for treating retinal artery occlusion damage.
3. Use of lifalast in the preparation of a drug for inhibiting the gene expression of at least one of Inos, Tnf-α, Il-1β, and IL-6.
4. Use of a composition containing lifalast in the preparation of a drug for inhibiting the gene expression of at least one of Inos, Tnf-α, Il-1β, and IL-6.
5. Use of lifalast in the preparation of drugs for reducing apoptosis of retinal ganglion cells.
6. The use according to any one of claims 1 to 5, characterized in that: The administration method of the drug is: intravitreal injection.
7. The use according to any one of claims 1 to 5, characterized in that: The drug acts on the microglial cell line BV2 or the retinal progenitor cell line R28.
8. A drug for treating retinal artery occlusion damage, characterized in that: Contains ritalidomide.
9. A drug for inhibiting the gene expression of at least one of Inos, Tnf-α, Il-1β, and IL-6, characterized in that: Contains ritalidomide.
10. The drug according to claim 8 or 9, characterized in that: It also comprises a pharmaceutically acceptable salt and a pharmaceutically acceptable carrier to form a clinically acceptable drug or preparation; the carrier is at least one of conventional diluents, excipients, fillers, adhesives, wetting agents, disintegrants, absorption promoters, surfactants, adsorption carriers, lubricants, flavoring agents, and sweeteners in the pharmaceutical field.
Citation Information
Patent Citations
Peptides for dry eye disease
CN110381920A
Collagen peptide-based medicament compositions and devices and methods of production and use thereof
CN113795273A
Crystalline pharmaceutical and methods of preparation and use thereof
US20090298869A1
Ocular distribution and pharmacokinetics of lifitegrast formulations
US20200009130A1
Cited By
Application of upatinib in preparation of medicine for treating acute retinal artery occlusion
CN121818649A
Use of lifitegrast in preparation of drug for treating retinal artery occlusion injury
WO2026031770A1
